The Global HIV Vaccine Enterprise (the Enterprise) is a unique alliance of independent organizations around the world dedicated to accelerating the development of a preventive HIV vaccine. The Enterprise will put forward a Scientific Strategic Plan for HIV vaccine research and development in 2010. Five working groups involving more than 100 scientists from around the world have been convened under the Enterprise to put forward recommendations for investment of finances and resources to further the field and the Enterprise's mission. These recommendations will comprise the 2010 Scientific Strategic Plan.
HISTORY of the SCIENTIFIC STRATEGIC PLAN
In the February 2005 issue of Public Library of Science (PLoS) - Medicine, the Enterprise published a scientific strategic plan for accelerating HIV vaccine research. The Plan described the major challenges facing the field at that time and made recommendations in six priority areas:
- Vaccine discovery
- Laboratory standardization
- Product development & manufacturing
- Clinical trials capacity
- Intellectual property issues
- Regulatory considerations
The Enterprise is a unique alliance of organizations that has the convening power to bring together an inclusive global alliance of top researchers, funders, advocacy groups, and stakeholders to catalyze fresh thinking, set new directions and advance global cooperation to develop an HIV vaccine.
NIAID Statement on National Black HIV/AIDS - February 01, 2010
Report on the CAVI/IAVI China AIDS Vaccine Network Meeting - January 21, 2010
The ANRS Announces New Round of Funding: Request for Applications - January 21, 2010